Enovis Corporation (ENOV)
$25.47
-0.76 (-2.90%)Delayed quote.
Price history
Daily close- Start
- $29.60
- Latest close
- $25.47
- Period change
- -13.95%
- Period low
- $17.43
- Period high
- $31.42
Key metrics
- Market cap
- $1.47B
- Volume
- 1.22M
- Average volume
- 1.54M
- 52-week range
- $16.70 – $31.67
- Beta
- 1.42
- Last dividend
- —
- EPS (TTM)
- -$9.28
- P/E ratio
- -1.28
- Revenue (TTM)
- $2.31B
- Net income (TTM)
- -$527.40M
- Total assets
- $3.74B
- Total debt
- $1.34B
- Cash and equivalents
- $13.04M
Key financials (trailing twelve months).
Company profile
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NYSE
- CEO
- Damien McDonald
- Employees
- 7,802
- Headquarters
- Lewisville, TX, US
- IPO date
- 2008-05-08
- Website
- https://www.enovis.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $2.25B | $2.11B | $1.71B |
| Gross profit | $1.35B | $1.18B | $990.78M |
| Operating income | -$18.87M | -$775.72M | -$65.71M |
| EBITDA | -$830.22M | -$481.03M | $169.73M |
| Net income | -$1.18B | -$825.49M | -$33.26M |
| Diluted EPS | -$20.86 | -$14.93 | -$0.61 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $36.39M | $48.17M | $36.19M |
| Total assets | $3.83B | $4.72B | $4.51B |
| Total liabilities | $2.34B | $2.15B | $1.09B |
| Total debt | $1.38B | $1.40B | $536.42M |
| Shareholders’ equity | $1.49B | $2.56B | $3.42B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $217.29M | $113.50M | $134.99M |
| Capital expenditure | -$197.38M | -$180.71M | -$122.22M |
| Free cash flow | $19.92M | -$67.21M | $12.77M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Oct 2, 2026 | Q2 2026Jul 3, 2026 | Q1 2026Apr 3, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Oct 3, 2025 | Q2 2025Jul 4, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $558.73M | $582.78M | $589.15M | $575.76M | $548.91M | $564.54M |
| Gross profit | $339.85M | $359.25M | $323.58M | $349.42M | $286.72M | $334.70M |
| Operating income | $3.38M | $17.41M | $20.27M | $48.25M | $9.04M | -$16.08M |
| EBITDA | $80.66M | $86.53M | $93.16M | -$425.02M | -$471.66M | $55.19M |
| Net income | $3.14M | -$1.19M | -$8.76M | -$520.59M | -$571.15M | -$36.74M |
| Diluted EPS | $0.06 | -$0.02 | -$0.15 | -$9.17 | -$10.06 | -$0.64 |
| Metric | Q3 2026Oct 2, 2026 | Q2 2026Jul 3, 2026 | Q1 2026Apr 3, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Oct 3, 2025 | Q2 2025Jul 4, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $13.04M | $12.56M | $33.13M | $36.39M | $33.62M | $44.07M |
| Total assets | $3.74B | $3.77B | $3.83B | $3.83B | $4.43B | $5.02B |
| Total liabilities | $2.24B | $2.29B | $2.35B | $2.34B | $2.41B | $2.44B |
| Total debt | $1.34B | $1.37B | $1.41B | $1.38B | $1.44B | $1.46B |
| Shareholders’ equity | $1.49B | $1.48B | $1.48B | $1.49B | $2.02B | $2.58B |
| Metric | Q3 2026Oct 2, 2026 | Q2 2026Jul 3, 2026 | Q1 2026Apr 3, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Oct 3, 2025 | Q2 2025Jul 4, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $71.49M | $75.03M | $23.95M | $88.54M | $82.58M | $47.77M |
| Capital expenditure | -$36.51M | -$43.90M | -$52.80M | -$56.25M | -$53.49M | -$44.37M |
| Free cash flow | $34.99M | $31.14M | -$28.85M | $32.29M | $29.09M | $3.40M |